Biontech Se-adr (BNTX) 13F Filing Data & Analysis (Q2 2026)

BNTX ranks #2137 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

BNTX is a top-conviction position for GSK plc — at 13.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BNTX belongs to FMR LLC, but the position matters far more to GSK plc, who has 13.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Squarepoint Ops LLC has added to its BNTX position for two straight quarters, increasing it by $71.5M to reach $76.2M today.

Flossbach Von Storch Se has trimmed its BNTX position for two straight quarters, cutting it by $192.3M while still holding $207.1M.

BNTX is up 1.8% today, but institutions show net selling of $21.8M this quarter — a divergence between today's price move and the underlying institutional flow.

BNTX reported a net loss of $1.1B in its latest fiscal year.

• Not yet profitable — net loss of $1.1B in the latest fiscal year
• Revenue grew 4.3% year over year
• Net income declined year over year, from -$665.3M to -$1.1B
• Generated $456.0M in positive operating cash flow
• Current ratio of 7.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range